OS THERAPIES INCORPORATED Diluted Shares Outstanding (Weighted Average)
OS THERAPIES INCORPORATED (OSTX) reported Diluted Shares Outstanding (Weighted Average) of 43.90 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-14
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 43.90M shares, a 74.82% increase year-over-year.
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 38.67M shares, a 82.00% increase year-over-year.
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 34.84M shares, a 68829.42% increase year-over-year.
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 31.96M shares, a 101.02% increase year-over-year.
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for fiscal 2025 was 29.25M shares, a 320.90% increase from fiscal 2024.
- OS THERAPIES INCORPORATED weighted average number of shares outstanding, diluted for fiscal 2024 was 6.95M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 43.90M shares 10-Q · filed 2026-08-14 | 41.36M shares 10-Q · filed 2026-08-14 | 39.14M shares derived: average of 3 quarters · filed 2026-08-14 | 37.34M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 38.67M shares 10-Q · filed 2026-05-18 | 36.76M shares derived: average of 2 quarters · filed 2026-05-18 | 35.16M shares derived: average of 3 quarters · filed 2026-05-18 | 32.65M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | 34.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 33.40M shares derived: average of 2 quarters · filed 2026-03-31 | 30.64M shares derived: average of 3 quarters · filed 2026-08-14 | 29.25M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 31.96M shares 10-Q · filed 2025-11-14 | 28.54M shares derived: average of 2 quarters · filed 2026-08-14 | 27.39M shares 10-Q · filed 2025-11-14 | 19.59M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | 25.11M shares 10-Q · filed 2026-08-14 | 25.06M shares 10-Q · filed 2026-08-14 | 15.47M shares derived: average of 3 quarters · filed 2026-08-14 | 15.58M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 21.25M shares 10-Q · filed 2026-05-18 | 10.65M shares derived: average of 2 quarters · filed 2026-05-18 | 12.40M shares derived: average of 3 quarters · filed 2026-05-18 | 10.80M shares derived: average of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | 50.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 7.97M shares derived: average of 2 quarters · filed 2026-03-31 | 7.31M shares derived: average of 3 quarters · filed 2026-03-31 | 6.95M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 15.90M shares 10-Q · filed 2025-11-14 | 10.94M shares derived: average of 2 quarters · filed 2025-11-14 | 9.25M shares 10-Q · filed 2025-11-14 | |
| 2024-06-30 | 5.99M shares 10-Q · filed 2025-08-18 | 5.85M shares 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | 5.99M shares 10-Q · filed 2025-05-15 | |||
| 2023-09-30 | 5.34M shares 10-Q · filed 2024-11-15 | 5.34M shares derived: average of 2 quarters · filed 2024-11-15 | 10.53M shares 10-Q · filed 2024-11-15 | |
| 2023-06-30 | 5.34M shares 10-Q · filed 2024-08-14 | 5.34M shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |